Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4751 | standard procedure Wiki | 1.00 |
| drug2786 | PRO questionnaire Wiki | 1.00 |
| drug3779 | Step monitoring Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Telemedicine allows clinicians to utilize modern telecommunication technology to provide healthcare services to patients including remote symptom monitoring. Given the spread of COVID-19 both locally and globally, is crucial to adapt accordingly in order to safely provide vulnerable cancer patient populations with optimal care while minimizing risk of exposure to COVID-19. In this study, the investigators will utilize remote monitoring of patients with cancer via weekly patient-reported outcome (PRO) collection through the Way to Health (W2H) smartphone application and step data through wearable Fitbit devices. Patients with incurable lung and gastrointestinal cancers will be recruited based on whether they receive their care in-clinic or remotely. They will respond to weekly phone-based symptom surveys and wear Fitbits that track step data. This data will be collated in a Palliative Care Assessment Dashboard (PROStep Dashboard) sent to clinicians prior to each oncology visit to help inform patient management. In this feasibility study, two arms of patients will be monitored with symptom surveys and Fitbits; the study will randomize these patients to either 1) receive feedback in the form of a personalized dashboard of symptoms and activity levels or 2) receive no feedback. A third arm of patients will be randomized to receive no feedback, symptom surveys, or Fitbit device. Clinicians for patients in each arm will receive the PROstep Dashboard. The study will determine feasibility of this monitoring approach, and compare patient adherence to symptom surveys and step data collection between the two intervention arms.
Description: Patient utility surveys will use a 5-point Likert scale for responses scored 1-5. The two co-primary outcomes will compare the scores for the following two questions, measured at 6 months, between ALL Arms. How well do you feel your oncology team understands your symptoms (e.g. nausea, vomiting, weight loss, etc.)? (1-5) How well do you feel your oncology team understands your activity level and ability to function? (1-5) Likert scale responses are defined as: 1 = Not at all; 2 = Slightly; 3 = Moderately; 4 = Considerably; 5 = Completely.
Measure: Patient perceptions of symptom management Time: These will be measured at 6 months after enrollment for each patient.Description: The following secondary outcomes will compare the same two questions measured at six months, between ARM A and ARM B: How well do you feel your oncology team understands your symptoms (e.g. nausea, vomiting, weight loss, etc.)? (1-5) How well do you feel your oncology team understands your activity level and ability to function? (1-5) Likert scale responses are defined as: 1 = Not at all; 2 = Slightly; 3 = Moderately; 4 = Considerably; 5 = Completely.
Measure: Additional analysis of the primary outcome between different arms (A and B) Time: These will be measured at 6 months after enrollment for each patient.Description: The following secondary outcomes will compare the same two questions measured at six months, between ARM A and ARM C: How well do you feel your oncology team understands your symptoms (e.g. nausea, vomiting, weight loss, etc.)? (1-5) How well do you feel your oncology team understands your activity level and ability to function? (1-5) Likert scale responses are defined as: 1 = Not at all; 2 = Slightly; 3 = Moderately; 4 = Considerably; 5 = Completely.
Measure: Additional analysis of the primary outcome between different arms (A and C) Time: These will be measured at 6 months after enrollment for each patient.Description: These outcomes will compare the scores for the following two questions, measured at 3 months (instead of 6 months like the primary outcome), between ALL Arms. How well do you feel your oncology team understands your symptoms (e.g. nausea, vomiting, weight loss, etc.)? (1-5) How well do you feel your oncology team understands your activity level and ability to function? (1-5) Likert scale responses are defined as: 1 = Not at all; 2 = Slightly; 3 = Moderately; 4 = Considerably; 5 = Completely.
Measure: Additional analysis of the primary outcome between all arms at 3 months Time: These will be measured at 3 months after enrollment for each patient.Description: We will compare cumulative adherence for patients in the intervention group (arm B and arm C). Each week, adherence will be defined as each week where the patient submits the weekly survey (i.e. adherence to PRO) and has step data for 4 of 7 days of the week (i.e. adherence to Fitbit platform), divided by the total number of weeks that the patient is enrolled in the trial. Comparison of mean patient adherence at three months for patients in arm B vs arm C Comparison of mean patient adherence at six months for patients in arm B vs arm C
Measure: Adherence Time: Each patient will be enrolled in the trial for a total of six months.Description: These will be measured using mean and median composite symptom scores reported by patients. The composite score is the sum of the scores for each domain in the PRO survey (0-32). The mean or median composite symptom score is the mean or median of all composite scores collected during the study. The PRO surveys use a 5-point scale (0 as LESS (None) to 4 as MORE (Very severe)). In the last 7 days, how OFTEN did you have NAUSEA?? In the last 7 days, how OFTEN did you have LOOSE OR WATERY STOOLS (DIARRHEA/DIARRHOEA)?? In the last 7 days, what was the SEVERITY of your CONSTIPATION at its WORST? In the last 7 days, what was the SEVERITY of your PAIN at its WORST? In the last 7 days, how much did your SHORTNESS OF BREATH INTERFERE with your usual or daily activities? In the last 7 days, how OFTEN did you have SAD OR UNHAPPY FEELINGS? In the last 7 days, how OFTEN did you feel ANXIETY? Over the past week I would generally rate my activity as:
Measure: Comparison of PRO scores (Arms B and C) Time: Each patient will be enrolled in the trial for a total of six months.Description: We will analyze trends in the Fitbit step data. Comparison of PRO scores between patients in arm B vs. arm C. Fitbit step data will be measured using mean daily step counts for all days in which Fitbit data is collected. Days where the patient does not have Fitbit data will be excluded from these calculations.
Measure: Fitbit step data Time: Each patient will be enrolled in the trial for a total of six months.Description: The utility to patients is measured using survey data at 3 and 6 months. These use a 5-point Likert Scale (1-5). We will report descriptive statistics for this data (mean and standard deviation) followed by t-tests between each arm.
Measure: Patient utility surveys (exploratory) Time: Each patient will be surveyed at 3 and 6 months following enrollment.Description: The utility to clinicians will be measured using survey data at three and six months. These similarly use a 5-point Likert scale (1-5) and we will report descriptive statistics for this survey data.
Measure: Clinician utility surveys (exploratory) Time: Each patient will be surveyed at 3 and 6 months following enrollment.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports